
Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.
Chapter from Interdisciplinary Care of Patients with EoE: Experts Offer Food for Thought video: Focuses on the pathophysiology and burden of EoE
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation

Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.

Join global experts Prof. Salvatore Oliva and Dr. Dhandapani Ashok for an educational symposium at ESPGHAN, as they discuss the burden and impact of underlying type 2 inflammation in eosinophilic esophagitis (EoE), and the importance of early diagnosis and management in pediatric patients.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses the significant risk of developing other atopic diseases among infants with early-onset atopic dermatitis.

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim provides an overview of itch in type 2 inflammatory skin diseases and explains how the shared and unique mechanisms that drive inflammation and itch mediate each disease in distinct ways.